Pratik S Velangi1, Ko-Hsuan Amy Chen1, Felipe Kazmirczak1, Osama Okasha1, Lisa von Wald1, Henri Roukoz1, Afshin Farzaneh-Far2, Jeremy Markowitz1, Prabhjot S Nijjar1, Maneesh Bhargava3, David Perlman3, Mehmet Akçakaya4, Chetan Shenoy5. 1. Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota. 2. Section of Cardiology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois. 3. Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota Medical School, Minneapolis, Minnesota. 4. Department of Electrical and Computer Engineering, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minnesota. 5. Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota. Electronic address: cshenoy@umn.edu.
Abstract
OBJECTIVES: This study aimed to determine the prevalence on cardiac magnetic resonance (CMR) of right ventricular (RV) systolic dysfunction and RV late gadolinium enhancement (LGE), their determinants, and their influences on long-term adverse outcomes in patients with sarcoidosis. BACKGROUND: In patients with sarcoidosis, RV abnormalities have been described on many imaging modalities. On CMR, RV abnormalities include RV systolic dysfunction quantified as an abnormal right ventricular ejection fraction (RVEF), and RV LGE. METHODS: Consecutive patients with biopsy-proven sarcoidosis who underwent CMR for suspected cardiac involvement were studied. They were followed for 2 endpoints: all-cause death, and a composite arrhythmic endpoint of sudden cardiac death or significant ventricular arrhythmia. RESULTS: Among 290 patients, RV systolic dysfunction (RVEF <40% in men and <45% in women) and RV LGE were present in 35 (12.1%) and 16 (5.5%), respectively. The median follow-up time was 3.2 years (interquartile range [IQR]: 1.6 to 5.7 years) for all-cause death and 3.0 years (IQR: 1.4 to 5.5 years) for the arrhythmic endpoint. On Cox proportional hazards regression multivariable analyses, only RVEF was independently associated with all-cause death (hazard ratio [HR]: 1.05 for every 1% decrease; 95% confidence interval [CI]: 1.01 to 1.09; p = 0.022) after adjustment for left ventricular EF, left ventricular LGE extent, and the presence of RV LGE. RVEF was not associated with the arrhythmic endpoint (HR: 1.01; 95% CI: 0.96 to 1.06; p = 0.67). Conversely, RV LGE was not associated with all-cause death (HR: 2.78; 95% CI: 0.36 to 21.66; p = 0.33), while it was independently associated with the arrhythmic endpoint (HR: 5.43; 95% CI: 1.25 to 23.47; p = 0.024). CONCLUSIONS: In this study of patients with sarcoidosis, RV systolic dysfunction and RV LGE had distinct prognostic associations; RV systolic dysfunction but not RV LGE was independently associated with all-cause death, whereas RV LGE but not RV systolic dysfunction was independently associated with sudden cardiac death or significant ventricular arrhythmia. These findings may indicate distinct implications for the management of RV abnormalities in sarcoidosis.
OBJECTIVES: This study aimed to determine the prevalence on cardiac magnetic resonance (CMR) of right ventricular (RV) systolic dysfunction and RV late gadolinium enhancement (LGE), their determinants, and their influences on long-term adverse outcomes in patients with sarcoidosis. BACKGROUND: In patients with sarcoidosis, RV abnormalities have been described on many imaging modalities. On CMR, RV abnormalities include RV systolic dysfunction quantified as an abnormal right ventricular ejection fraction (RVEF), and RV LGE. METHODS: Consecutive patients with biopsy-proven sarcoidosis who underwent CMR for suspected cardiac involvement were studied. They were followed for 2 endpoints: all-cause death, and a composite arrhythmic endpoint of sudden cardiac death or significant ventricular arrhythmia. RESULTS: Among 290 patients, RV systolic dysfunction (RVEF <40% in men and <45% in women) and RV LGE were present in 35 (12.1%) and 16 (5.5%), respectively. The median follow-up time was 3.2 years (interquartile range [IQR]: 1.6 to 5.7 years) for all-cause death and 3.0 years (IQR: 1.4 to 5.5 years) for the arrhythmic endpoint. On Cox proportional hazards regression multivariable analyses, only RVEF was independently associated with all-cause death (hazard ratio [HR]: 1.05 for every 1% decrease; 95% confidence interval [CI]: 1.01 to 1.09; p = 0.022) after adjustment for left ventricular EF, left ventricular LGE extent, and the presence of RV LGE. RVEF was not associated with the arrhythmic endpoint (HR: 1.01; 95% CI: 0.96 to 1.06; p = 0.67). Conversely, RV LGE was not associated with all-cause death (HR: 2.78; 95% CI: 0.36 to 21.66; p = 0.33), while it was independently associated with the arrhythmic endpoint (HR: 5.43; 95% CI: 1.25 to 23.47; p = 0.024). CONCLUSIONS: In this study of patients with sarcoidosis, RV systolic dysfunction and RV LGE had distinct prognostic associations; RV systolic dysfunction but not RV LGE was independently associated with all-cause death, whereas RV LGE but not RV systolic dysfunction was independently associated with sudden cardiac death or significant ventricular arrhythmia. These findings may indicate distinct implications for the management of RV abnormalities in sarcoidosis.
Authors: Sana M Al-Khatib; William G Stevenson; Michael J Ackerman; William J Bryant; David J Callans; Anne B Curtis; Barbara J Deal; Timm Dickfeld; Michael E Field; Gregg C Fonarow; Anne M Gillis; Christopher B Granger; Stephen C Hammill; Mark A Hlatky; José A Joglar; G Neal Kay; Daniel D Matlock; Robert J Myerburg; Richard L Page Journal: Heart Rhythm Date: 2017-10-30 Impact factor: 6.343
Authors: Olga Bondarenko; Aernout M Beek; Mark B M Hofman; Harald P Kühl; Jos W R Twisk; Willem G van Dockum; Cees A Visser; Albert C van Rossum Journal: J Cardiovasc Magn Reson Date: 2005 Impact factor: 5.364
Authors: Yoko Mikami; Aidan Cornhill; Bobak Heydari; Sebastien X Joncas; Fahad Almehmadi; Mohammed Zahrani; Mahmoud Bokhari; John Stirrat; Raymond Yee; Naeem Merchant; Carmen P Lydell; Andrew G Howarth; James A White Journal: J Cardiovasc Magn Reson Date: 2016-11-14 Impact factor: 5.364
Authors: Christopher M Kramer; Jörg Barkhausen; Scott D Flamm; Raymond J Kim; Eike Nagel Journal: J Cardiovasc Magn Reson Date: 2013-10-08 Impact factor: 5.364
Authors: Gillian Murtagh; Luke J Laffin; John F Beshai; Francesco Maffessanti; Catherine A Bonham; Amit V Patel; Zoe Yu; Karima Addetia; Victor Mor-Avi; Joshua D Moss; D Kyle Hogarth; Nadera J Sweiss; Roberto M Lang; Amit R Patel Journal: Circ Cardiovasc Imaging Date: 2016-01 Impact factor: 7.792
Authors: Rajat Kalra; Shray Malik; Ko-Hsuan Amy Chen; Fredrick Ogugua; Pal Satyajit Singh Athwal; Andrew C Elton; Pratik S Velangi; Mohamed F Ismail; Sanya Chhikara; Jeremy S Markowitz; Prabhjot S Nijjar; Lisa von Wald; Henri Roukoz; Maneesh Bhargava; David Perlman; Chetan Shenoy Journal: Circ Arrhythm Electrophysiol Date: 2021-09-01
Authors: Aaron T O'Brien; Katarzyna E Gil; Juliet Varghese; Orlando P Simonetti; Karolina M Zareba Journal: J Cardiovasc Magn Reson Date: 2022-06-06 Impact factor: 6.903
Authors: Harold Mathijssen; Marloes P Huitema; Annelies L M Bakker; Fatima Akdim; Hendrik W van Es; Jan C Grutters; Marco C Post Journal: Int J Cardiovasc Imaging Date: 2021-09-29 Impact factor: 2.357
Authors: George Markousis-Mavrogenis; George Poulos; Theodoros Dimitroulas; Aikaterini Giannakopoulou; Clio Mavragani; Vasiliki Vartela; Dionysia Manolopoulou; Genovefa Kolovou; Paraskevi Voulgari; Petros P Sfikakis; George D Kitas; Sophie I Mavrogeni Journal: Diagnostics (Basel) Date: 2021-03-15